Interventional Endoscopy News

The use of glucagon-like peptide-1 receptor agonists exponentially increased in recent years for treating diabetes and obesity, with benefits also observed in other cardiometabolic syndromes.

The explosive popularity of glucagon-like peptide-1 receptor agonists for diabetes and weight loss may have revolutionized obesity management, but their widespread use has also sparked concerns — and ignited a turf war — in the endoscopy suite.

The presence of mucosal damage on upper gastrointestinal endoscopy was associated with a 76% greater risk for developing Parkinson’s disease, underscoring the need for “increased vigilance” among these patients, according to a cohort study.

An AI-assisted endoscopy module increased adenoma detection, including sessile serrated lesions, during colonoscopy and is recommended in routine practice to reduce incidence of post-procedure colorectal cancer, according to researchers.

As the launch of UnitedHealthcare’s Gold Card program approaches, the AGA continues to urge the insurer to reconsider implementation of a program that could affect various gastrointestinal procedures and “threaten patient health.”

Revised quality indicators released by the ACG and ASGE highlight the importance of adenoma and sessile serrated lesion detection rates as well as adequate bowel preparation for improving the technical performance of colonoscopy.

The ACG and ASGE have released an updated quality indicators document, intended to serve as a framework to improve performance of endoscopic procedures.

Although glucagon-like peptide-1 receptor agonist use prior to upper endoscopy was linked to a higher rate of retained gastric contents, evidence supports prolonged fasting as the “optimal approach” rather than routine discontinuation.

Adults with obesity and type 2 diabetes had reductions in body weight and HbA1c 1 year after undergoing an endoscopic procedure that resurfaces the duodenum lining, according to top-line results from a real-world registry study.